Erasca, Inc.

ERAS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Assets
Cash & Equivalents $73.8M $67.7M $93.1M $284.2M $360.5M $65.4M
Accounts Receivable — — — — — —
Inventory — — — — — —
Total Current Assets $286.2M $308.8M $320.7M $444.5M $420.0M $120.0M
Property, Plant & Equipment $13.3M $16.3M $22.3M $24.8M $16.0M $1.8M
Goodwill — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — —
Total Assets $396.2M $502.5M $395.3M $514.9M $501.4M $124.8M
Liabilities
Accounts Payable $981.0K $468.0K $2.0M $23.0M $4.7M $878.0K
Total Current Liabilities $28.5M $31.4M $26.2M $48.7M $26.2M $13.7M
Long-Term Debt — — — — — —
Total Liabilities $71.0M $79.0M $78.6M $103.1M $44.9M $17.4M
Stockholders' Equity
Retained Earnings $-892.2M $-767.7M $-606.0M $-481.0M $-238.2M $-115.4M
Total Stockholders' Equity $325.2M $423.5M $316.7M $411.9M $456.5M $-114.0M